デュピクセント®を開始した喘息患者の登録

基本情報

NCT ID

NCT04287621

ステータス

実施中（募集終了）

試験のフェーズ

-

試験タイプ

観察

目標被験者数

718

治験依頼者名

Regeneron Pharmaceuticals

概要

The primary objective of the study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life. This includes characterization of: * Patient demographics (eg, gender, age, and race) * Patient baseline characteristics (eg, prior medications and procedures, medical history, asthma history, weight, height) The secondary objectives of the study are: * To characterize real-world use patterns of DUPIXENT® for asthma * To assess the long-term effectiveness of DUPIXENT® in asthma patients in a real-world setting * To assess effectiveness on comorbid type 2 inflammatory conditions in asthma patients treated with DUPIXENT® * To collect long-term safety data on study participants in the real-world setting

対象疾患

介入

依頼者（Sponsor）

実施施設 (12)